KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with AstraZeneca. Under the terms of the agreement, KINAXO will apply its technology platform to support one of AstraZeneca’s oncology programs.
KINAXO will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. Since protein modifications play pivotal roles in many cellular processes (eg cell death or DNA repair) such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets. Financial details of the agreement were not disclosed.
Dr Henrik Daub, CTO at KINAXO commented: “Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action. We are delighted to apply our expertise to support AstraZeneca’s research in such highly promising fields of investigation. This collaboration further strengthens KINAXO’s position as a preferred technology partner for global pharmaceutical companies.”